Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Aug 3 2015

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

CL-H1T contains fast-dissolving promethazine and sumatriptan. This novel migraine product is being developed as a treatment for migraine headache pain and migraine-induced nausea and vomiting (MINV).

"Many patients with migraine headaches also suffer from nausea and vomiting," said Bernard Schachtel, MD, Chief Scientific Officer at Charleston Laboratories, Inc. "CL-H1T contains a known medication for migraine headache with specially formulated promethazine, a safe and effective anti-emetic medication," Dr. Schachtel said. "This Phase I study will identify the bioavailability of both active ingredients in this new combination treatment."

"This announcement is another example of the depth of our innovation pipeline and our overall commitment to research and development in the area of pain management," said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories, Inc. "We look forward to getting this product to physicians and their migraine patients who need the dual therapy that CL-H1T provides."

Charleston Laboratories currently has a development and commercialization partner, Daiichi Sankyo, Inc., for its first product, CL-108, which is completing Phase 3 clinical trials.